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Abstract
Objective
To test the hypothesis of ‘horizontal epidemiology’, i.e. that psychosocial difficulties (PSDs),
such as sleep disturbances, emotional instability and difficulties in personal interactions,
and their environmental determinants are experienced in common across neurological and
psychiatric disorders, together called brain disorders.
Study Design
Amulti-method study involving systematic literature reviews, content analysis of patient-
reported outcomes and outcome instruments, clinical input and a qualitative study was
carried out to generate a pool of PSD and environmental determinants relevant for nine dif-
ferent brain disorders, namely epilepsy, migraine, multiple sclerosis, Parkinson’s disease,
stroke, dementia, depression, schizophrenia and substance dependency. Information from
these sources was harmonized and compiled, and after feedback from external experts, a
data collection protocol including PSD and determinants common across these nine disor-
ders was developed. This protocol was implemented as an interview in a cross-sectional
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study including a convenience sample of persons with one of the nine brain disorders.
PSDs endorsed by at least 25% of patients with a brain disorder were considered associ-
ated with the disorder. PSD were considered common across disorders if associated to 5
out of the 9 brain disorders and if among the 5 both neurological and psychiatric conditions
were represented.
Setting
The data collection protocol with 64 PSDs and 20 determinants was used to collect data
from a convenience sample of 722 persons in four specialized health care facilities in
Europe.
Results
57 of the PSDs and 16 of the determinants included in the protocol were found to be experi-
enced across brain disorders.
Conclusion
This is the first evidence that supports the hypothesis of horizontal epidemiology in brain
disorders. This result challenges the brain disorder-specific or vertical approach in which
clinical and epidemiological research about psychosocial difficulties experienced in daily
life is commonly carried in neurology and psychiatry and the way in which the corresponding
health care delivery is practiced in many countries of the world.
Introduction
Psychosocial difficulties (PSDs), such as sleep disturbances, emotional instability and difficul-
ties in personal interactions and in work are prevalent in people with neurological and psychi-
atric disorders–which we here call ‘brain disorders’. PSDs are commonly used to estimate
disease severity in neurological disorders [1]. In psychiatric disorders they are also used as diag-
nostic criteria [2]. Information about the PSDs people with brain disorders experience is as a
result routinely obtained both in clinical practice and research.
Information about PSDs—whether it comes from clinical practice or research—is typically
reported for each brain disorder in particular and only in exceptional cases are comparisons
across brain disorders made. In a multi-method review, Wittchen et al. tellingly found that
only with very few exceptions European studies concentrate on single disorders [3]. They
found no study that systematically examined the difficulties associated with the full range of
brain disorders. Where comparisons across brain disorders are targeted, these are usually
restricted to single PSD, mostly body functions such as fatigue [4] or pain [5].
A focus on single conditions, in a silo-like manner is in some cases justifiable and necessary.
For example, biomedical research must focus on the differential brain mechanisms that cause
condition-specific symptoms. Similarly, life course approaches targeting shedding light on the
epidemiology of different disorders, i.e. risk factors for depression, or on disorder-specific out-
comes, i.e. impact of anxiety disorders in the adolescence on education achievement, are inevi-
tably disorder-specific [6, 7]. The question is whether a disease-specific approach is also
appropriate when identifying, understanding the impact of and treating the PSDs that people
with brain disorders experience in their daily lives.
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There is no good reason to believe that PSDs are fundamentally different between brain dis-
orders, especially if we operationalize PSDs in terms of the World Health Organisation’s Inter-
national Classification of Functioning, Disability and Health (ICF) [8]. Based on its conceptual
model of functioning and disability, impairments in body functions and structures, activity
limitations and participation restrictions are not a direct consequence of biological mecha-
nisms of the health condition, but rather an outcome of the interaction between those mecha-
nisms and features of the person’s environment and personal factors [8].
Relying on this understanding, we hypothesize that there are PSDs—defined as impairments
of mental functions and impairments of body functions under central nervous system control,
activity limitations and participation restrictions—that are common in people with brain disor-
ders despite variations in symptomatology, aetiology, and the biochemical basis of their
disorders.
There are several reasons that intuitively support the hypothesis of commonalities in PSDs
across brain disorders. People with different brain disorders are subject to similar physical,
social, and attitudinal influences, such as the built environment, support of the family, attitudes
about their illnesses, and views about personal responsibility. Even though intensity can vary,
the kinds of PSDs people experience in their lives, and which are influenced by these factors,
are probably similar. Clinicians working with patients with neurological and psychiatric disor-
ders are familiar with the fact that there are some common difficulties that their patients expe-
rience, such as sleep problems, difficulties with affect, maintaining personal relationships and
holding a job. There is also research that supports this clinical experience [4, 5, 9–11]. Finally,
it is well known that co-morbidity within brain disorders is very high, making it more intuitive
to detach PSD from specific brain disorders [3].
If common PSDs are experienced by people with different brain disorders, it is reasonable
to assume that there are also cross-cutting determinants of these PSDs. Using these determi-
nants as a basis for developing interventions or strategies targeting PSDs across brain disorders
would be more cost-effective than is currently the case. In fact, promising cross-cutting strate-
gies are already recommended for instance for improving the experience of care for people
using mental health services [12]. Lessons could be learned from the effectiveness of such strat-
egies. The marginal utility of investing in common interventions and strategies further
increases their cost-effectiveness to society.
The project called PARADISE (Psychosocial fActors Relevant to BrAin DISorders in
Europe, www.paradiseproject.eu) funded under the FP7 by the European Commission, gave us
the opportunity to test the hypothesis of commonalities across brain disorders. The PARA-
DISE consortium was composed of 10 partners across Europe with clinical, epidemiological
and public health expertise. Patients’ organizations were informed about the project and
involved in it through the European Brain Council. In the present study we use a multi-method
approach to test the hypothesis that people with different brain disorders experience PSDs and
determinants in common. This hypothesis was called ‘horizontal epidemiology’ to highlight
the difference from the standard, brain disorder-specific approach.
Material and Methods
Ethics statement
All study-relevant documentation and the written informed consent forms provided to the par-
ticipants were approved by the Ethics Committees of the Neurological Institute Carlo Besta
IRCCS Foundation in Milan, Italy, the Institute of Psychiatry and Neurology in Warsaw,
Poland, the teaching hospital La Princesa of the University of Madrid in Madrid, Spain and the
Järvenpää Addiction Hospital in Haarajoki, Finland. The present study has therefore been
Horizontal Epidemiology of Brain Disorders
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performed in accordance with the ethical standards laid down in the 1964 Declaration of Hel-
sinki and its later amendments.
The present study has two parts. In the first one, PSDs and their determinants relevant
across brain disorders were identified, while in the second part the hypothesis of ‘horizontal
epidemiology’ was challenged. Each part is described in detail as follows.
Identifying PSDs and their determinants relevant across brain disorders
To challenge the hypothesis of horizontal epidemiology we first needed to select brain disor-
ders sufficiently diverse in terms of aetiology, biochemical bases, signs and symptoms. The
selected brain disorders were: dementia, depression, epilepsy, migraine, multiple sclerosis
(MS), Parkinson´s disease (PD), schizophrenia, stroke and substance dependency. These disor-
ders have been selected for: 1) Being among the most burdensome disorders according to the
Global Burden of Disease study [13]; 2) Occurring throughout Europe and across demographic
and socio-economic categories; 3) Including disorders that have both intermittent (epilepsy
and depression) and continuous (dementia and substance use disorders) symptomatology and
consequences.
Secondly, we followed a multi-method approach depicted in Fig 1: (1) systematic literature
reviews, (2) content analysis of patient-reported outcomes (PROs) and outcome instruments,
(3) clinical input and (4) a qualitative study. Information from all sources was (5) harmonized
and compiled and (6) a data collection protocol developed also including feedback from an
external expert consultation. The protocol included all potentially relevant PSDs and their
determinants across brain disorders. (7) This protocol was implemented in a cross-sectional
study.
(1) Systematic literature reviews
Nine systematic literature reviews, one for each brain disorder were carried out, and have been
published separately [14–18]. The literature between 2005 and 2010 was searched to identify
PSDs and their determinants reported in intervention studies, longitudinal observational and
qualitative studies (S1 File, S2 File). The PSDs and determinants reported were extracted as
well as all Patient Reported Outcomes (PROs) and any other outcome instrument used. A
detail description of the approach followed in the PARADISE literature reviews is presented in
Świtaj et al. [15].
(2) PROs
Clinical researchers who carried out the brain disorder-specific reviews selected the three
PROs or outcome instruments that, in their experience treating patients with the disorders in
the project, best captured the PSDs their patients experienced. Twenty-seven PROs and out-
come instruments were selected.
(3) Clinical input
The clinical researchers, on the basis of the results of their literature reviews, and their own
clinical expertise, provided for each brain disorder determined which PSDs were the most
salient for their patients.
(4) Qualitative study
Focus groups and patient interviews gathered information about PSDs and their determinants.
One focus group was conducted for each brain disorder, with three exceptions: for substance
Horizontal Epidemiology of Brain Disorders
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dependency two gender-specific groups were held to facilitate the discussion of gender-specific
issues; two focus groups were conducted for stroke to accommodate different cognitive levels
of stroke patients; and for dementia individual interviews were conducted, or, for very severely
compromised patients, interviews with their caregivers were substituted.
(5) Compilation and selection for data collection protocol
The extracted PSDs and determinants from the literature reviews and the qualitative study
were grouped by underlying concept and named using ICF terms during a two-day workshop,
in which all researchers participated. The items or content of the 27 PROs and outcome mea-
sures as well as the PSDs and determinants resulting from the clinical input were also grouped
using ICF terms after applying standardized linking rules described by Cieza et al. [19]. Using
the ICF as a standard language made it possible to compare PSDs and determinants from the
literature reviews, PROs and outcome measures, the expert input and the qualitative studies.
Potentially relevant PSDs and determinants had to be selected for inclusion in the data col-
lection protocol. This was done separately for PSDs and determinants. Since we wanted to test
the hypothesis of horizontal epidemiology we had to make sure that even PSDs and determi-
nants relevant to small group of disorders were included. At the same time we had to keep the
balance between comprehensiveness and practicability. The procedure for selecting PSDs is
Fig 1. PARADISE approach with literature reviews, content analysis of outcome instruments, clinical
input and qualitative study. PARADISE multi-method approach with systematic literature reviews, content
analysis of patient-reported outcomes (PROs) and outcome instruments, clinical input and a qualitative study.
Information from all sources was harmonized and compiled and a data collection protocol developed also
including feedback from an external expert consultation. The protocol included all potentially relevant PSDs
and their determinants across brain disorders. This protocol was implemented in a cross-sectional study.
doi:10.1371/journal.pone.0136271.g001
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shown in Fig 2. We included in the data collection protocol those determinants identified in at
least two of the literature reviews or in at least two brain disorders in the qualitative study.
The selection of PSDs and determinants was critically evaluated by a panel of six external
experts. The members of this independent panel were selected based on their outstanding
expertise as clinicians and researchers and for holding leadership positions in Europe in the
field of brain disorders. The experts were asked to provide additional PSDs and determinants
they thought were missing in the protocol based on their experience of patients with the
selected brain disorders.
(6) Construction and piloting of the data collection protocol
For most of the PSDs and determinants, questions from questionnaires and clinical instru-
ments and national and international health surveys were identified and used for the data col-
lection protocol. Instruments used were: WHOWorld Health Survey (http://www.who.int/
healthinfo/survey/en/); WHO Composite International Diagnostic Interview (CIDI) [20];
WHO Disability Assessment Schedule 2.0 (WHODAS II) [21]; Hospital Anxiety and Depres-
sion Scale (HADS) [22]; Quality of Life Instrument for Young Hemorrhagic Stroke Patients
(HSQuale) [23]; Sickness Impact Profile (SIP) [24]; Symptom Checklist (SCL-90) [25]; Sched-
ule for Clinical Assessment in Neuropsychiatry (SCAN) [26]; Stroke Adapted-Sickness Impact
Profile (SA-SIP) [27]; Stroke Impact Scale (SIS) [28]; WHO Survey on Health and Health
Fig 2. Decision tree used for selecting relevant psychosocial difficulties across brain disorders. The starting point of the decision tree was the list of
psychosocial difficulties (PSD) addressed in the 27 patient reported outcome (PRO) or outcome instruments identified in the literature reviews. If a PSD was
addressed in at least one of the PROs or outcome instruments and had also been identified in at least two of the three sources of information (literature
reviews, qualitative study and clinical input), this PSD was selected for inclusion into the data collection protocol. If a PSD had only been included in one of
the sources of information, then if it had been identified in the literature reviews of at least two brain disorders and in those in > 20% of the studies included in
the reviews, then the PSD was also included in the PARADISE protocol. If not, then if it had been included in the patient input studies for more than three
brain disorders, or in the clinical input for more than three brain disorders, in both cases it was included in the protocol.
doi:10.1371/journal.pone.0136271.g002
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System Responsiveness (HSQR) (http://www.who.int/responsiveness/surveys/en/); WHO
Quality of Life (WHOQoL) [29]. In a few cases, where no standard question was available, new
questions were developed. The response options were homogenized to be the same for all PSDs
questions, namely None, Mild, Moderate, Severe, Extreme, Don’t know and not applicable.
The response options for environmental determinants ranged from No positive influence to
Strong positive influence and from No negative influence to Strong negative influence. The
determinants referring to personal characteristics, such as personality or self-efficacy, were col-
lected with standard questionnaires, such as the 10-item short version of the Big Five Inventory
[30] and items of the General Self-Efficacy Scale [31]. For those instruments the original ques-
tions and response options were kept. The data from these questionnaires were not analyzed
for this paper.
The protocol also contained a section in which participants were asked 1) whether there are
problems or difficulties not mentioned during the interview but which they would like to add
and 2) to mention up to five problems or difficulties in areas of life that are the most troubling
or burdensome for them. For these, the participants were also asked when it was that they first
occurred, how they had changed over time, and whether something influenced their change.
The feasibility and clarity of the protocol were piloted in interviews with four patients, two
with depression, one with schizophrenia and one with Parkinson’s disease.
(7) Implementation of the data collection protocol
The data collection protocol was implemented in a cross-sectional study on a convenience
sample of 80 persons per brain disorder. Patients were interviewed by a trained clinical
researcher using the protocol. For the purpose of describing the study population, demographic
information, age, the impact of comorbidities and a general health question were asked.
Comorbidities were accessed with the Self-reported Comorbidities Questionnaire (SCQ) [32].
Using the SCQ a summary score on the impact of comorbidity is derived by adding the up to
three points obtained from each of the included 12 health conditions: one point for its pres-
ence, one if treatment is received, and one if it causes decrements in functioning. In addition,
to determine the severity of the brain disorder, standard disease-specific measures routinely
used in the recruiting centres, were used. In the case of epilepsy, no instrument was routinely
used, so severity of epilepsy was assessed by frequency of seizures in the last year and the num-
ber of anti-epileptic drugs taken.
Patient inclusion criteria were that the main diagnosis was one of the nine brain disorders
and the patient was at least 18 years old with sufficient facility with the language of the country
to understand the purposes of consent. The patient was asked to agree to participate and to
sign the informed consent form. For dementia patients not able to provide consent, the caregiv-
ers were asked to give consent and to participate in the interviews as proxies.
The data of the patients with dementia and schizophrenia were collected at the Instytut Psy-
chiatrii i Neurologii in Warsaw, Poland, the data of those with epilepsy, migraine, multiple scle-
rosis, Parkinson´s disease and stroke at the Instituto Nazionale Neurologico “Carlo Besta” in
Milan, Italy, of those with substance dependency at the Järvanpää Addiction Hospital, Haara-
joki, Finland and of those with depression at the the Hospital Universitario de La Princesa in
Madrid, Spain.
Testing the hypothesis of ‘horizontal epidemiology’
It was previously decided that a PSD was associated with a brain disorder if at least 25% of
patients reported it as a difficulty, independently of the severity (Mild, Moderate, Severe or
Extreme). It was also decided that a PSD could be said to be commonly experienced across
Horizontal Epidemiology of Brain Disorders
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brain disorders if 1) the PSD was associated to 5 out of the 9 brain disorders and 2) among the
5 both neurological conditions (epilepsy, migraine, multiple sclerosis, Parkinson’s disease,
stroke) and psychiatric conditions (dementia, depression, schizophrenia, substance depen-
dency) were represented. Even though it could be questioned whether dementia is a neurologi-
cal or a psychiatric condition, we followed the ICD-10 and classified it as psychiatric. The same
criteria were used for testing whether there are environmental determinants with cross-cutting
influence, either positive or negative. For the calculation of the percentages the response option
don’t know and not applicable were considered missing data.
To describe our sample we also used descriptive statistics. The severity of the brain disorder
was determined by dividing each patient group into categories of mild, moderate and severe
according to standardized cut-offs found in the literature for the corresponding instruments.
Results
The multi-method approach used to identify potentially relevant PSDs and their determinants
across brain disorders resulted in the so called PARADISE data collection protocol, which
includes 64 PSDs and 59 determinants of PSD. Columns one to three of Table 1 present the
PSDs included in the protocol by name, by ICF code, and the question used to operationalize
them. Columns 4 to 12 of Table 1 summarize the results of the cross-sectional study and pres-
ent for each PSD and each brain disorder, the percentage of people who had reported difficul-
ties. Those cells above 25% are marked in bold. Table 2 shows demographic characteristics as
well as the allocation to severity group of the 722 people participating in the cross-sectional
study.
In 57 of the 64 PSDs more than 25% of the sample of at least 5 brain disorders reported diffi-
culties. In all 57 both neurological and psychiatric brain disorders were represented. Problems
with mental functions like being emotionally affected, depressive mood, worry and anxiety,
stress and pain were, however, meaningfully more frequently than our 25% cut-off: these PSDs
were endorsed by more than 45% of all persons with brain disorders independently of the
underlying condition. Problems with the level of energy and tiredness were even more frequent
and endorsed for all included brain disorders by more than 70% of the different samples.
Regarding activities and participation domains, problems in carrying out daily routine were
endorsed by more than 40% of the persons with any condition, followed by problems in mobil-
ity, lifting and carrying objects, walking and economic sufficiency, endorsed by more than ca.
40% of all subsamples but epilepsy and PD.
Table 3 presents environmental determinants with percentage of people who felt that these
determinants influenced their PSDs, either positively or negatively. Seventeen of the 20 envi-
ronmental determinants fulfil our criteria as common influences of PSDs. Extremely important
determinants across conditions were both care and attitudes of health professionals, and help
and assistance as well as attitudes of the family, endorsed by more than 80% and 70% of the
sample regardless of brain disorder, respectively. More than 84% of persons with any condition
endorsed the impact of medication in their PSD, with the exception of substance dependency
(50% endorsement rate). The four environmental determinants not fulfilling our criteria were
‘costs of the medication’, ‘assistive devices’, ‘access to alcohol’ and ‘access to illegal drugs’. As
can be seen from Table 3, in general terms the percentages of people endorsing the influence of
environmental determinants on their PSD were very high in all groups.
Discussion
The hypothesis of horizontal epidemiology in brain disorders, namely, that there are PSDs and
determinants experienced in common across brain disorders was supported by the evidence in
Horizontal Epidemiology of Brain Disorders
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Table 2. Demographic characteristics of the persons participating in the study implementing the PARADISE data collection protocol.
Epilepsy Migraine Multiple
Sclerosis
Parkinson Stroke Dementia Depression Schizophrenia Substance
dependency
N 80 80 80 80 80 80 81 81 80
Country
(data
collection) §
Italy Italy Italy Italy Italy Poland Spain Poland Finland
Age (years) Mean 41,23 44,54 41,03 61,24 59,84 81,03 54,81 38,38 39,56
SD 11,99 12,12 8,74 10,45 14,36 5,49 14,73 14,03 13,15
Gender (%) Female 50,0% 86,3% 65,0% 40,0% 43,8% 78,8% 82,7% 53,1% 37,5%
Setting (N) Inpatient 28 0 9 24 79 10 3 56 80
Outpatient
care
31 80 70 56 1 68 77 9 0
Home care 21 0 1 0 0 1 0 1 0
Other - - - - - 1 1 15 -
General
living
situation (%)
Living
independently
and alone
11,3% 12,5% 15,0% 13,8% 10,0% 25,0% 34,6% 23,5% 41,3%
Living
independently
with others in
a household
88,8% 87,5% 83,8% 86,3% 83,8% 55,0% 59,3% 65,4% 42,5%
Marital
status (N)
Married 36 42 45 61 57 25 32 6 16
Marriage-like
relationship
6 11 5 4 5 0 5 4 13
Separated 3 5 4 2 3 0 4 0 1
Divorced 2 2 1 1 0 2 10 8 10
Widowed 1 3 2 5 2 48 13 3 2
Never married 32 17 23 7 13 5 17 60 38
Highest level
of education
completed
(%)
No formal
schooling
0,0% 0,0% 1,3% 0,0% 0,0% 0,0% 2,5% 0,0% 0,0%
Less than
primary school
0,0% 0,0% 0,0% 1,3% 0,0% 3,8% 14,8% 0,0% 3,8%
Primary
school
completed
1,3% 1,3% 1,3% 13,8% 22,5% 18,8% 16,0% 4,9% 35,0%
Secondary
school
completed
28,8% 18,8% 23,8% 26,3% 22,5% 3,8% 11,1% 4,9% 32,5%
High school
completed
50,0% 48,8% 51,3% 43,8% 40,0% 40,0% 17,3% 44,4% 17,5%
University
completed
20,0% 28,8% 20,0% 13,8% 12,5% 27,5% 27,2% 43,2% 6,3%
Post graduate
degree
completed
0,0% 2,5% 2,5% 1,3% 2,5% 6,3% 11,1% 2,5% 5,0%
Working
sample (%)
66,3% 67,5% 72,5% 33,8% 25,0% 0,0% 27,2% 8,6% 6,3%
Disease
duration
(years)
Mean 18,67 21,13 7,66 6,26 4,00 3,69 12,63 13,03 12,16
SD 12,32 14,60 6,94 4,40 6,48 2,70 11,57 11,83 8,67
(Continued)
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this paper. This finding challenges the brain disorder-specific, silo-like, or vertical approach in
which clinical and epidemiological research about psychosocial difficulties is commonly car-
ried out and corresponding health care delivery practiced in many countries of the world.
To our knowledge this is the first time that this hypothesis has been formulated and tested
by means of an approach integrating information from literature, PROs and clinical instru-
ments, expert clinical knowledge and most importantly the involvement of persons with brain
disorders themselves. Results of the steps that led to the development of the PARADISE data
Table 2. (Continued)
Epilepsy Migraine Multiple
Sclerosis
Parkinson Stroke Dementia Depression Schizophrenia Substance
dependency
Disease
severity
Instrument* CRS MIDAS EDSS Hoehn &
Yahr
NIHSS MMSE HDRS CGI ADS**
N 79 80 80 80 55 80 81 81 34
Mean (SD) na 27,16
(22,92)
2,13
(1,74)
na 4,93
(4,39)
21,10
(2,89)
19,70 (5,49) na
Cut-off Mild
Severity
= 1 <6 <3 = 1 or 1.5 1 to 5 25 <14 = 2 or 3  13
No of persons 24 9 64 15 37 6 11 32 1
Cut-off
Moderate
Severity
= 2  6 & 
20
 3 & 
5
= 2 or 2.5 6 to
14
 10 & <
25
 14 & 
18
= 4 or 5  14 &  21
No of persons 28 27 9 58 14 74 26 49 7
Cut-off High
Severity
= 3 >20 > 5 = 3 or 4  15 < 10 >18 = 6 or 7  22
No of persons 27 44 7 7 29 0 44 0 26
Comorbidity
score (SCQ
score***)
Mean 2,36 2,63 1,18 3,00 5,87 5,86 12,56 2,72 8,84
SD 2,97 2,55 2,17 2,63 4,87 4,17 5,09 3,14 4,76
In general,
how would
you rate your
health
today? (%)
Very good 11,3% 3,8% 15,0% 3,8% 2,5% 3,8% 2,5% 11,1% 1,3%
Good 43,8% 47,5% 43,8% 51,3% 37,5% 26,3% 18,5% 37,0% 38,8%
Neither poor
nor good
35,0% 36,3% 32,5% 41,3% 41,3% 57,5% 24,7% 42,0% 41,3%
Poor 6,3% 10,0% 7,5% 3,8% 13,8% 11,3% 39,5% 9,9% 17,5%
Very poor 3,8% 2,5% 1,3% 0,0% 5,0% 1,3% 14,8% 0,0% 1,3%
§ Data collection centers: dementia and schizophrenia, Instytut Psychiatrii i Neurologii in Warsaw, Poland; epilepsy, migraine, multiple sclerosis, Parkinson
´s disease and stroke, Instituto Nazionale Neurologico “Carlo Besta” in Milan, Italy; substance dependency, Järvanpää Addiction Hospital, Haarajoki,
Finland and depression, Hospital Universitario de La Princesa in Madrid, Spain.
* HDRS: Hamilton Depression Rating Scale; CRS: Clinical Rating of Severity; MIDAS: Migraine Disability Assessment; EDSS: Expanded Disability Status
Scale; Hoehn & Yahr: Hoehn & Yahr Score; NIHSS: National Institutes of Health Stroke Scale; CGI: Clinical Global Impression (CGI); MMSE: Mini Mental
State Examination; ADS: Alcohol Dependence Scale.
** In substance dependency, 44 persons had alcohol dependence as their main diagnosis. The data reported here refer to the 34 of those from whom the
ADS data were available. Mean is not reported because of the low N. For all other substance dependency conditions, the intention was to collect data with
the ‘Severity of Dependence Scale’. There were, however, a larger number missing data and the results are, therefore, not reported.
*** SCQ Score: Self-reported Comorbidities Questionnaire. The summary score is derived by adding the up to three points obtained from each reported
health conditions: one point for its presence, one if treatment is received, and one if it causes decrements in functioning
doi:10.1371/journal.pone.0136271.t002
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collection protocol and determinants have been recently published [14, 16–18, 33–35]. Here
we concentrate exclusively on the results and discussion of the testing of the hypothesis of hori-
zontal epidemiology.
We were surprised by the result that 56 of 64 PSDs fulfilled the criteria we established to test
the hypothesis of horizontal epidemiology and that for several PSD much larger rates of
endorsement across brain conditions were observed. As expected due to the overlap with
symptoms of mental and neurological disorders, PSDs related to mental health functions, espe-
cially being emotionally affected, depressive mood, worry and anxiety, and coping with stress
were highly relevant and affected nearly half of our participants independently of their brain
disorder. The same pattern was observed for pain, with extremely high endorsement rates in
persons with migraine (94%) but also in persons with depression and substance dependency
(over 80%). Further highly relevant PSD across disorders were problems in carrying out daily
routine, in mobility and in keeping economic sufficiency. These results confirm, first of all, the
impact of brain disorders on people’s lives. This impact goes beyond impairments, such as
sleep disturbances, to fundamental difficulties in major life areas, such as keeping economic
sufficiency. Similar results have already been shown for single conditions such as migraine, PD,
Table 3. Environmental determinants included in the data collection protocol and the percentage of persons who experienced them as having a
positive or negative influence in their psychosocial difficulties.
Determinant Epilepsy Migraine Multiple
Sclerosis
Parkinson Stroke Dementia Depression Schizophrenia Substance
dependency
Medication 98.8 90.0 91.3 93.8 92.5 86.3 84.0 92.6 50.0
Costs of the medication 18.8 48.8 68.8 10.0 13.8 60.0 19.8 37.0 17.5
Other treatments 28.8 30.0 42.5 35.0 46.3 31.3 54.3 61.7 96.3
The environment around
you
30.0 57.5 57.5 48.8 18.8 96.3 50.6 42.0 58.8
Public transportation 50.0 55.0 43.8 30.0 22.5 50.0 45.7 46.9 48.8
Assistive devices 22.5 13.8 16.3 16.3 65.0 25.0 34.6 2.5 5.0
Weather or climate 21.3 90.0 77.5 67.5 15.0 68.8 72.8 77.8 61.3
Awareness of health
condition people have
58.8 75.0 67.5 48.8 35.0 61.3 63.0 74.1 83.8
Help and assistance
from family
98.8 86.3 87.5 81.3 98.8 97.5 81.5 90.1 95.0
Attitudes of family 96.3 88.8 87.5 92.5 98.8 95.0 69.1 81.5 83.8
Help and assistance
from friends
80.0 66.3 80.0 38.8 66.3 57.5 72.8 63.0 76.3
Attitudes of friends 80.0 67.5 81.3 75.0 71.3 66.3 59.3 63.0 76.3
Help and assistance of
peers or colleagues
67.5 56.3 57.5 22.5 46.3 41.3 33.3 61.7 81.3
Attitudes of peers and
colleagues
77.5 61.3 63.8 48.8 50.0 53.8 35.8 60.5 78.8
Attitudes of strangers 41.3 30.0 37.5 27.5 15.0 62.5 43.2 63.0 36.3
Care from health
professionals
100.0 83.8 82.5 95.0 97.5 90.0 90.1 91.4 96.3
Attitudes of health
professionals
93.8 83.8 86.3 93.8 97.5 83.8 80.3 85.2 86.3
Health problems of other
members of family
23.8 65.0 46.3 22.5 21.3 67.5 70.4 66.7 50.0
Access to alcohol 2.5 7.5 10.0 2.5 1.3 1.3 9.9 13.6 58.8
Access to illegal drugs 0.0 0.0 6.3 0.0 0.0 0.0 2.5 6.2 51.3
doi:10.1371/journal.pone.0136271.t003
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MS, stroke, Dementia, depression or epilepsy [8,17–22]. Similarities regarding PSD have also
been shown in studies across mental disorders applying the WHO Disability Assessment
Schedule (WHODAS 2.0), a generic instrument for health and disability valid across diseases
and disorders, also mental disorders [21]. Exemplary articles report that problems are experi-
enced to different extents in all six WHODAS domains (cognition, mobility, self-care, getting
along with others, participation in society, and life activities) by persons with any mood, anxi-
ety or substance use disorder [36] or persons with bipolar affective disorder and schizophrenia
[37]. The novelty of our work consists of showing that people experience the same kind of diffi-
culties regardless of the brain disorder they have, in a broad range of brain disorders specific
PSD selected in a multi-step process and in altogether nine brain disorders very different
regarding aetiology, symptoms and progression.
Similarly surprising clear results were observed for environmental determinants: 16 from 20
determinants fulfilled the criteria we established a priori, and the endorsement rates for these
determinants were generally much higher than the 25% criteria, regardless of brain condition.
Extremely high endorsement rates across brain disorders for care and attitudes of health pro-
fessionals, and help and assistance as well as attitudes of the family stress the importance of
these relationships for PSD. These results are in line with the acknowledged importance of fam-
ily support in different brain disorders, for instance in PD and Dementia [38], and in line with
current efforts to improve service user experience in adult mental health, where one quality
statement is assuring that users “and their families or carers, are treated with empathy, dignity
and respect” [12]. Again, the novelty of our work consists rather of showing that these determi-
nants are valid across brain disorders.
Our results were unexpected because we included a large number of PSDs and determinants
in the data collection protocol so as not to miss potentially relevant PSDs and determinants.
One may object that the result was affected by the overly lenient cut-off of 25% for relevant
PSD and 5 out of 9 brain disorders. But, one out of four is already highly significant, and we
had no reason to set that threshold higher. In the case of using 5 out of 9 brain disorders as the
threshold for commonality, we feel very confident that this was sufficient since the results
would have been unchanged if a higher cut-off 7 out of 9 brain disorders was used.
One might object as well that a major limitation of our study was the lack of a comparison
of PSDs experienced by persons with disorders that cause chronic ill health, other than brain
disorders. It is certainly our hypothesis that many of the PSDs shared by brain conditions
would be shown to be experienced by persons with other chronic health conditions, even those
that are not brain disorders. A recent study to create a 'generic ICF core set' found that for a
large clinical population (N = 9863) with very diverse health conditions, several functioning
domains–mobility, self-care and interpersonal relationships, among others–were experienced
in common and explained their general health status [39]. Many of these categories were
indeed the same as the PSDs reported in this study. At the same time, for some health condi-
tions such as asthma, or disease groups, such as lung diseases, it is likely that there are fairly
specific PSD that are highly relevant both to research and treatment, but might not be common
problems across all chronic health conditions. Analogously, we assume that for brain disorders,
despite the overlap with other chronic health conditions, there may well be specific PSD that
are more closely linked to these disorders than to other health conditions.
Now that we have evidence in support of the hypothesis of horizontal epidemiology, what
are the consequences? We see consequences in clinical practice, research and policy making.
While highly specialized brain-disorder knowledge and specific diagnostic criteria are
required for diagnosis, a broader, more cross-cutting approach is necessary to understand the
impact of brain disorders in daily life and to develop and implement interventions and strate-
gies that directly address this impact. Applying interventions across brain disorders opens the
Horizontal Epidemiology of Brain Disorders
PLOS ONE | DOI:10.1371/journal.pone.0136271 September 9, 2015 19 / 24
door to a more efficient health care provision in which health professionals can rely on com-
mon clinical experience and knowledge transfer to address similar PSD. The Canadian experi-
ence in increasing access to cognitive-behavioural therapy irrespective of the disorder, is an
example of how to achieve cost-effectiveness with a horizontal approach [40].
There is also some evidence that a cross-cutting strategy to health care in brain disorders is
cost-effective especially in low resource settings where every effort needs to be made to spread
limited care resources [41, 42]. The results of the PARADISE project suggest that in the care of
persons with brain disorders high resource countries might well learn from the experience of
implementing cross-cutting intervention strategies in low resource settings.
In research, we see in light of our results the need for studies that capture the impact of
brain disorders horizontally. As noted, Wittchen et al. found no European study that systemati-
cally examined impact across brain disorders [3] and in PARADISE we widened that search to
include international studies and found the same results (the database for this work can be
obtained from the corresponding author). As we have seen with the surprising results of PAR-
ADISE, cross-cutting horizontal research in PSD in brain disorders pays off in terms of broad-
ening our understanding of the impact of these disorders in daily life, and on what are
important determinants of this impact.
We also see the need for an outcome measure to describe the impact of living with a brain
disorder that is sensitive to change over time and able to capture similarities and differences
between disorders. This is required to evaluate effectiveness and cost-effectiveness of interven-
tions across brain disorders, as has been pointed out by other authors. The widely-used Short
Form-36 [43] and the EQ-5D [44] have been shown not to be sensitive to people with mental
disorders [45, 46]. While there are many condition-specific PROs addressing problems in func-
tioning and health-related quality of life in persons with specific brain disorders, there is no
generic instrument addressing difficulties that persons with brain disorders experience in their
life. The results of the PARADISE project form the ideal basis to develop a generic, brain disor-
der outcome measure, as recently reported [47, 48].
Health policy-makers, unlike clinicians and researchers, now recognize the importance of
brain disorders as a whole, in order to understand the genetic, biochemical and structural
impairments behind brain disorders [49]. In addition, a better and broader understanding of
PSDs that people with these disorders confront daily is needed. Knowledge about the environ-
mental determinants of those difficulties, as well as the determinants of their deterioration or
improvement, can lead to a wide range of interventions that can truly make a difference to peo-
ple’s lives. Investments in research focusing on the development of social and psychological
interventions are urgently needed. People with brain disorders themselves need to hear that
exhaustion of medical interventions does not mean that nothing else can be done. The results
of this study show that much more can be done to improve the lives of persons with brain dis-
orders with interventions targeting PSDs as well as the environment. As has been shown in pre-
vious research, interventions targeting both affected persons and the environment can be
extremely effective [50]. Theoretically the scale of the benefit of these interventions can be
enlarged if they are implemented across disorders.
This project has limitations that must be considered while interpreting our results. Firstly, it
has been carried out from a solely European perspective and data was collected in four Euro-
pean countries, even though the literature reviewed in the preparation phase was international.
This may speak against the generalizability of its results that should be validated with data of
other regions of the world. Secondly, in some steps of our multi-method approach we relied
solely on our research group, for instance to select PROs and salient PSDs. Although all part-
ners participating in the study are acknowledged experts in their areas, we recognize a risk of
having prioritized their preferences, and considering a broader expert pool could have led to a
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different selection of PROs and salient PSDs. We have been, however, very conservative
throughout the study and paid attention to include even PSDs and determinants relevant to
small group of disorders. Our selection of PSDs and determinants was also critically evaluated
by a panel of six external experts, who did not belong to our consortium. Thirdly, it has to be
taken into account that the sample included in our study was a convenience one and that the
relationship between the severity of a disorder and endorsement rates of PSD and determinants
could not be explored, among others. Studies with larger and representative samples, balanced
regarding disease severity, are therefore required to confirm our results, and to explore their
robustness when disease severity is considered. Fourth, determinants not fulfilling our criteria
were access to alcohol and illegal drugs. We acknowledge that these factors involve very sensi-
tive issues that are difficult to address in an interview and that we have here a risk of social
desirability bias. Last but not least, and as mentioned before, our criteria for deciding whether
the hypothesis of horizontal epidemiology, though intuitive, were nevertheless neither sup-
ported by evidence nor verified with any statistical tests. We welcome arguments from readers
suggesting more appropriate criteria.
Conclusion
In conclusion, our study provides first evidence that supports the hypothesis of horizontal epi-
demiology in brain disorders: Psychosocial difficulties and environmental determinants of
those difficulties are experienced in common across brain disorders. This result challenges the
brain disorder-specific or vertical approach in which clinical and epidemiological research
about psychosocial difficulties experienced in daily life is commonly carried in neurology and
psychiatry and the way in which the corresponding health care delivery is practiced in many
countries of the world.
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